問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taipei Tzu Chi Hospital (在職)

Division of Endocrinology

Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare (在職)

Division of Endocrinology

更新時間：2023-09-19

吳忠擇Wu, Chung-Ze
  • Principal Investigator
  • Clinical Trial Experience (year) 12 years 9 個月

Recruiting Trial

0Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

吳忠擇

Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Endocrinology

List

10Cases

2009-08-01 - 2011-07-31

Others

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2013-04-01 - 2015-06-30

Phase III

A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE III STUDY TO ASSESS THE EFFICACY, SAFETY AND TOLERABILITY OF ALEGLITAZAR MONOTHERAPY COMPARED WITH PLACEBO IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2D) WHO ARE DRUG-NAÏVE TO ANTI-HYPERGLYCEMIC THERAPY

  • Condition/Disease

    TYPE 2 DIABETES

  • Test Drug

    Aleglitazar (RO0728804)

Participate Sites
3Sites

Terminated3Sites

2019-12-01 - 2025-05-31

Phase III

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Selonsertib in Subjects with Moderate to Advanced Diabetic Kidney Disease

  • Condition/Disease

    Moderate to Advanced Diabetic Kidney Disease

  • Test Drug

    Selonsertib

Participate Sites
2Sites

Terminated2Sites

2012-02-01 - 2015-02-28

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2010-12-01 - 2012-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

2011-07-01 - 2013-12-31

Phase III

A prospective, randomized, double-blind trial comparing the long-acting basal insulin analogue LY2963016 and Lantus® in adult patients with type 2 diabetes

  • Condition/Disease

    Type 2 diabetes

  • Test Drug

    LY2963016

Participate Sites
8Sites

Terminated8Sites

2012-03-01 - 2014-04-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Terminated9Sites

2019-04-01 - 2022-12-15

Phase III

A Randomized, Phase 3, Open-Label Trial Comparing the Effect of LY3298176 versus Titrated Insulin Degludec on Glycemic Control in Patients with Type 2 Diabetes (SURPASS-3)

  • Condition/Disease

    Type 2 Diabetes Mellitus

  • Test Drug

    LY3298176

Participate Sites
9Sites

Terminated9Sites

2011-09-01 - 2018-12-31

Phase III

A multicentre, international, randomised, parallel group, double blind study to evaluate Cardiovascular safety of linagliptin versus glimepiride in patients with type 2 diabetes mellitus at high cardiovascular risk.

  • Condition/Disease

    type 2 diabetes

  • Test Drug

    Linagliptin

Participate Sites
16Sites

Terminated16Sites

2013-01-01 - 2015-04-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB